MISSISSAUGA, ONTARIO--(Marketwire - August 29, 2008) - BioSyent Inc. (“BioSyent”)(TSX VENTURE: RX) today released a summary of its financial results for the second quarter 2008. For the six months ending June 30, 2008, sales increased by 17% from $447,946 in first half of 2007 to $524,573 in first half of 2008. Both Pharmaceutical and Bio-friendly Insecticide divisions experienced growth. The company incurred a loss of ($167,845) in the first half 2008 compared to a loss of ($177,374) in first half of 2007. This loss is predominantly due to the higher pharmaceutical operating expenses for the establishment of the hospital division and the launch of Ciprofloxacin Injection, which was first shipped in May 2008.
